The SynBio Innovation Accelerator, a Collaboration between Codexis and Casdin Capital, Enables $10 million Investment in Molecular Assemblies, Inc.
November 04, 2021 08:00 ET
|
Codexis, Inc.
Funding to accelerate MAI’s go-to-market strategy as the enzyme engineering phase nears completion Represents the second early-stage company investment enabled by the SynBio Innovation Accelerator ...
Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
November 03, 2021 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a...
Codexis to Report Third Quarter 2021 Financial Results on November 4
October 21, 2021 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India
October 18, 2021 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party...
Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin
September 09, 2021 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and...
Codexis to Participate in Upcoming Virtual Healthcare Conferences
September 07, 2021 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Confirms Receipt of Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company
August 25, 2021 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the Company received...
Codexis Reports Second Quarter 2021 Financial Results
August 05, 2021 16:05 ET
|
Codexis, Inc.
Record Product Revenue of $14.7M, up 227% YOY Record Product Gross Margin of 71% Company Raises Guidance for 2021 Total Revenue to $98 - 103 M and 2021 Product Revenue to $59 - 63 M REDWOOD...
Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient
August 02, 2021 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif. and KALAMAZOO, Mich., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec,...
Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient
July 26, 2021 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif. and KALAMAZOO, Mich., July 26, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec,...